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A WEB-BASED SYSTEM SUPPORTING STRATEGICAL DECISIONS IN
WORLD WIDE URELATED DONOR SEARCH
Feldmann, U.1, Bochtler, W.1, Eberhard, H.-P.1, Mueller, C.R.1
ZKRD Zentrales Knochenmarkspender-Register, Ulm, Germany.
Most active unrelated stem cell donor registries in the world
are participating in the cooperation of Bone Marrow Donors
Worldwide (BMDW). Formally, BMDW is a service provided
by the Dutch registry Europdonor collecting all data, providing
them back to the contributors and making them directly acces-
sible via a web based matching program. Unfortunately, HLA
information is limited for many donors, in particular where
DRB1 alleles are missing or only tested at low or intermediate
resolution. We are using our own copy of the BMDW data to
generate haplotypes frequencies per registry for HLA-A,B-
,DRB1. HLA-A and B are analyzed using serological nomen-
clature and DRB1 using a resolution of 2 and 4 digits as far as
the data for each registry permits. These haplotypes frequencies
are used for a web based system prototyped in our intranet,
which calculates the probability of ﬁnding a donor who is a
match for HLA-A and B (serology) and for DRB1 (allele level)
by performing subsequent test on partially typed donors. In the
calculation of the conditional match probabilities the program
correctly interprets all broad serological designations and mul-
tiple allele codes using the individual frequencies for each reg-
istry. Where there are test candidates in several registries, the
system can also indicate which donors according to their origin
or partial typing status are most likely to turn out to be matches.
This provides a highly intelligent sorting of BMDW match lists.
The program is currently implemented as a CGI-script using
PERL and typically takes 5–20 seconds on a 1.5 GHz XEON
including a full molecular BMDW match run. The program has
immediately become an indispensable tool for the analysis of all
difﬁcult donor searches.
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COMPARABLE RESULTS OF UMBILICAL CORD BLOOD AND HLA
MATCHED SIBLING DONOR HEMATOPOIETIC STEM CELL TRANSPLANT
AFTER REDUCED-INTENSITY PREPARATIVE REGIMEN FOR ADVANCED
HODGKIN’S LYMPHOMA
Majhail, N.S.1, Defor, T.E.1, Brunstein, C.G.1, Wagner, J.E.1,
Weisdorf, D.J.1, Miller, J.S.1, Arora, M.1, Tomblyn, M.R.1,
McGlave, P.B.1, Slungaard, A.1, Burns, L.J.1 Blood and Marrow
Transplant Program, University of Minnesota, Minneapolis, MN.
The lower regimen-related toxicity of reduced-intensity con-
ditioning (RIC) preparative regimens has extended the oppor-
tunity for allogeneic stem cell transplantation (alloSCT) and its
potential graft-versus-lymphoma effect to patients with ad-
vanced Hodgkin’s lymphoma (HL). In this pilot study, we com-
pared the safety and efﬁcacy of RIC alloSCT in 21 adults with
chemosensitive primary refractory or relapsed HL using either
umbilical cord blood (UCB-9) or matched sibling donors
(MSD-12). Indications for RIC alloSCT were age 	55 years
with HLA matched sibling donor (19%), age 	45 years with
UCB donor (5%), extensive prior therapy including previous
autologous stem cell transplant (ASCT) (67%), or major co-
morbidity (22%). Of the 14 patients who had failed prior ASCT,
median duration of post-transplant CR was 11 months (range,
3–54). Patient demographics, disease characteristics at initial
diagnosis, and at relapse prior to alloSCT were comparable
except for a younger age in the UCB cohort (median 28 years vs
42 years for MSD, P  .04). Results are shown in Table 1.
Neutrophil recovery occurred earlier in the MSD group. All
patients had sustained donor engraftment by day 60. Cumu-
lative incidence of grade III/IV acute graft-versus-host disease
and 180-day treatment-related mortality were comparable. Two
patients who underwent MSD alloSCT received donor-lympho-
cyte infusion for post-transplant relapse with resultant partial
responses lasting 3 and 6 months. With a median follow-up of
17 and 24 months for the UCB and MSD groups, respectively,
the 2-year progression-free survival (PFS) for UCB is 25%
compared to 20% for MSD alloSCT. The median time to
disease progression was 4 months for the UCB group and 6
months for the MD group; all relapses occurred within 1 year of
alloSCT. Patients with relapsed disease or longer post-ASCT
CR (12 months) were more likely to be alive and free of
progressive disease than patients with primary refractory disease
or short CR. Our results suggest comparable outcomes for RIC
alloSCT using UCB or MSD source in adults with high-risk,
advanced HL. Since many patients lack a matched sibling or
unrelated donor, UCB grafts can provide an effective and safe
alternative. In addition, alloSCT using RIC is associated with
durable PFS in a selected subgroup of patients. Further studies
are ongoing to identify patients who would beneﬁt the most by
this approach (Table 1).
Table 1. Post-Transplant Outcomes
UCB
(n  9)
MSD
(n  12)
P-
Value
Cell dose (107
NC/kg)
Median
(range)
3.8 (2.3–5.3) 10.0 (7.9–16.4) <.01
HLA 1–2
antigen
mismatch
9 (100%) 1 (8%) <.01
Neutrophil
engraftment
(days)
Median
(range)
10 (6–28) 7 (5–12) .02
Complete
donor
chimerism
Day 21 6 (67%) 12 (100%) .06
Day 60 9 (100%) 12 (100%) -
Acute GVHD Grade II–IV 6 (67%) 7 (58%) .70
Grade III–IV 3 (33%) 4 (33%) .99
Chronic GVHD 1 (11%) 4 (33%) .24
CR after
alloSCT
8 (89%) 9 (75%) .42
Treatment
related
mortality
100 days 1 (11%) 2 (17%) .80
180 days 2 (22%) 3 (25%) .88
Followup
(months)
Median (range) 17 (4–51) 24 (9–53)
2-year PFS
(months)
(95% CI) 25% (0–55%) 20% (0–44%) .67
2-year OS
(months)
(95% CI) 51% (16–86%) 48% (19–77%) .93
NC-nucleated cells; HLA-human leukocyte antigem; GVHD-
graft-versus-host-disease; CR-complete remission; CI-conﬁ-
dence intervals.
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MOBILIZATION OF PERIPHERAL BLOOD CD34 STEM CELLS IN A
HEAVILY PRE-TREATED PEDIATRIC MEDULLOBLASTOMA PATIENT US-
ING AMD3100 AND G-CSF
Robertson, K.A.1, Pradhan, K.1, Goebel, S.1, Renbarger, J.1, Abonour, R.1,
Calandra, G.B.2, McFarland, R.T.2, Haut, P.R.1 1. Indiana Univeristy
School of Medicine, Indianapolis, IN; 2. AnorMed Inc., Langley, BC,
Canada.
Autologous peripheral blood stem cell transplantation has
been beneﬁcial in the setting of recurrent medulloblastoma,
however many of these patients are heavily pre-treated, making
conventional mobilization of peripheral blood stem cells with
G-CSF alone difﬁcult. The recent development of AMD3100 as
an inhibitor of the binding of SDF-1/CXCL12 to its receptor
CXCR4 in the marrow stem cell compartment has resulted in
signiﬁcant enhancement in the mobilization of peripheral blood
stem cells. This has met with considerable success in adults with
phase III trials under way, however there is little pediatric
experience with the use of AMD3100. We report here the use of
AMD3100 to mobilize peripheral blood CD34 cells from a
heavily pre-treated 11 year-old girl with recurrent medulloblas-
toma. DM was diagnosed with stage IV medulloblastoma in Feb
2004 and was treated with surgical resection, radiation, and
maintenance chemotherapy including cisplatin, CCNU, and
vincristine. Prior to her 5th cycle of chemotherapy she experi-
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enced a (biopsy proven) relapse. She went on to receive salvage
chemotherapy including carboplatin and cytoxan with stabiliza-
tion of disease, but without shrinkage in her tumor. Attempts to
collect peripheral blood stem cells upon recovery from chemo-
therapy using G-CSF at a dose of 24mcg/kg/day were unsuc-
cessful with only 1  105CD-34 positive stem cells per kg
collected over 3 days. In order to attempt to collect enough stem
cells for an autologous stem cell transplant, we obtained consent
from the AnorMED corporation and our institutional review
board for a PBSC collection using 4 days G-CSF at 10 mcg/kg
sc followed by 240 mcg/kg AMD3100 sc and subsequent aphere-
sis 10 hours later. We collected PBSCs for three days and
repeated this cycle a second time 30 days later, which allowed us
to collect 1.3  106CD34 positive stem cells per kg, more than
an order of magnitude greater than with G-CSF alone. There
were no untoward toxicities including no GI upset, paresthesias,
or injection site reactions, which have been previously reported
with adult patients. Pharmacokinetics were performed and were
similar to adults.
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IMPACT OF HIGH-RESOLUTION HLA MATCHING ON OUTCOMES OF
UNRELATED DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION
Jang, J.H.1, Kang, S.Y.1, Park, J.S.1, Choi, J.H.1, Lim, H.Y.1,
Kim, H.C.1 Department of Hematology-Oncology, Ajou University
School of Medicine, Suwon, Korea.
Objective: We assessed the impact of high-resolution geno-
typic results of human leukocyte antigen (HLA) for all major
class I and II loci between donors and recipients in the outcome
of unrelated hematopoietic stem cell transplantation (HSCT).
Methods: Between 1999 and 2005, high-resolution genotyping
for HLA-A, -B, -C and -DRB1 was performed for 23 unrelated
HSCT. All the patients were typed as HLA identical by sero-
logic technique and then they were also typed HLA identical by
high resolution technique. Unrelated bone marrow transplan-
tation using DNA-based high resolution HLA compatibilities
were considered in the analyses of clinical outcomes such as
hematopoietic engraftment, acute GVHD, and survival. And
then, we compared with patients who received related HSCT
and also unrelated HSCT data from IBMTR. Results: Median
follow up duration was 9 months (1–51). Fifteen patients were
male and 8 were female. Median age was 22 years (range 6–52).
Median time from diagnosis to transplantation was 7 months
(range 4–63). Eight patients of acute myeloid leukemia (AML),
6 of chronic myeloid leukemia (CML, 2 of 6 were in blast crisis),
4 of acute lymphoid leukemia (ALL), 3 of severe aplastic anemia,
and each case of juvenile myelomonocytic leukemia and myelo-
dysplastic syndrome were enrolled. Median value of total nu-
cleated cell and CD34 positive cell count was 3.51 (1.06–
20.7)  108/kg and 4.88 (1.33–46.9)  106/kg, respectively. The
conditioning regimen and prophylaxis for graft versus host dis-
ease (GVHD) were not different from conventional HSCT
except one case of non-myeloablative transplantation. Median
value of granulocytic (absolute granulocyte count 	500/mm3)
and platelet (	20,000/mm3) engraftment were D  16, D  17,
respectively. Grade II acute GVHD developed in 4 patients (2
patients subsequently proceeded to chronic GVHD). Treatment
related mortality was 8.7% (2 out of 23 patients). Median value
of overall survival duration was 30 months. For AML patients,
3-year survival rate was 72.9%. Conclusions: Our survival data
for unrelated HSCT based on high resolution genotyped HLA
matching was inferior to related HSCT and superior to unre-
lated HSCT (of as expected). Although the sample size is small,
the survival data of AML patients (CR1) was superior to the
survivals of related HSCT as well as that of unrelated HSCT.
We suggest that transplantation using unrelated donors selected
by high-resolution genotype identity improves the transplanta-
tion outcomes.
IMMUNE RECONSTITUTION
218
TRANSCRIPTIONAL MAPPING OF THE ANTI-VIRAL T CELL RESPONSE
SHOWS THAT IMPAIRED MEMORY DIFFERENTIATION CAUSES T CELL
DYSFUNCTION
Haining, W.N.1, Ebert, B.1,2, Subramanian, A.2, Golub, T.1,2,
Kaech, S.3, Wherry, E.J.4, Nadler, L.M.1 1.Dana-Farber Cancer In-
stutute, Boston, MA; 2. Broad Institute of Harvard and MIT, Cam-
bridge, MA; 3. Yale University, New Haven, CT; 4. Wistar Institute,
Phliadelphia, PA.
Human T cells responding to viral pathogens after HSCT can be
dysfunctional and ineffective even when present in adequate num-
bers. The basis for this qualitative, rather than quantitative, T cell
defect is not known.We hypothesized that impaired differentiation
of naive T cells into memory T cells causes a qualitative T cell
defect. We, therefore, studied CD8 T cell memory differentiation
in 2 murine models of LCMV infection: an acute infection in
which virus-speciﬁc T cells are fully functional and a chronic
infection model in which T cells are present in normal numbers
but are dysfunctional. In order to deﬁne how the differentiation
state of dysfunctional T cells in chronic infection differ from those
in acute infection, we generated gene expression proﬁles from
naive (day 0), effector (day 7 [d7]), and memory (day 30 [d30]) T
cells using oligonucleotide microarrays. In acute infection, T cell
states were so distinct that 100% of naive, effector, and memory
samples could be correctly classiﬁed, using a k-Nearest-Neighbor
prediction classiﬁer (kNN). Next, we hypothesized that the signa-
ture of normal memory T cells would contain gene-sets known to
be important in memory differentiation. We found that Stat-5
target genes were the most enriched gene-sets in memory cells
relative to naive cells of 	400 gene-sets tested (P  .004 by
permutation testing). This is consistent with the central role of
Stat-5 signaling in memory development. Lastly, we determined
where dysfunctional d30 T cells from chronic infection lie relative
to the “differentiation-space” of acute infection. None of the
chronic d30 T cell samples were classiﬁed as memory by kNN
prediction; all were misclassiﬁed as effectors. However, chronic
d30 T cells were not simply persistent effectors because chronic
d30 T cells showed marked differences in gene expression pattern
compared to d7 effectors. Thus, dysfunctional T cells in chronic
viral infection fail to complete normal memory differentiation and
are arrested in a distinct, effector-like phase. Our results show that
the disruption of memory differentiation causes qualitative T cell
dysfunction, and that this altered differentiation can be detected by
gene-expression proﬁling. We are now generating a global map of
antigen-speciﬁc T cell differentiation in humans. This gene-ex-
pression-based approach to evaluating immune reconstitution will
identify the mechanisms limiting the recovery of T cell memory
after HSCT.
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EXPRESSION OF INDIVIDUAL KILLER IMMUNOGLOBULIN-LIKE RECEP-
TOR (KIR) GENES MEASURED BY QUANTITATIVE REAL-TIME-PCR DI-
VIDES BLOOD NATURAL KILLER (NK) CELLS INTO THREE DEVELOP-
MENTALLY DISTINCT POPULATIONS
Cooley, S.A.1, Xiao, F.1, Pitt, M.1, McCullar, V.1, Bergemann, T.L.1,
McQueen, K.2, Parham, P.2, Miller, J.S.1 1. University of Minnesota,
Minneapolis, MN; 2. Stanford University, Palo Alto, CA.
Although hematopoietic cell transplant strategies that use KIR-
ligand mismatching to generate alloreactive NK cells have been
associated with improved clinical outcomes, the contributing ef-
fects of the fundamental processes regulating individual KIR ex-
pression are poorly understood. To study KIR emergence during
NK cell reconstitution, we created and validated a novel Quanti-
tative Real Time PCR (Q-PCR) expression typing assay to mea-
sure comparative KIR mRNA expression at the single gene level.
TaqMan primers and probes were designed for 13 KIR genes and
compared to genotyping. Analysis of 435 reactions run on mononu-
clear cells (5–15% NK cells) from 36 normal volunteers showed
excellent concordance between expression typing and genotyping:
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